Human Papillomavirus

Clinical Trial Begins with HPV Vaccine Candidate

Published in Cancer Weekly, February 17th, 1997

MedImmune, Inc., Gaithersburg, Maryland, announced it has begun enrollment for a Phase l clinical trial with a vaccine for the prevention of human papillomavirus (HPV) disease of the genital tract.

MedImmune believes that the trial, conducted at the University of Rochester Medical Center, Rochester, New York, represents the first evaluation in humans of a preventative HPV vaccine. There are currently no vaccines to prevent these common sexually transmitted diseases (STDs) that affect 24 to 40 million men and women in the United States. HPVs are responsible for the development of genital warts and cervical cancer.

MedImmune announced on December 11,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-02-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry